We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celgene (CELG) to Post Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Celgene Corporation is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell. Last quarter, the company reported a negative earnings surprise of 1.40%.
Celgene outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past one year. The stock gained 10.5% during this period, compared with a decline of 14.4% for the industry.
Celgene’s track record has been pretty decent with the company beating earnings estimates thrice in the trailing four quarters. Overall, the company has delivered an average positive surprise of 5.08%.
Let's see how things are shaping up at the company ahead of this announcement.
Factors at Play
Celgene’s key product, Revlimid, should continue to act as the main growth driver in the first quarter, driven by share gains in important markets and longer treatment duration in newly diagnosed multiple myeloma (MM). Other key products – Pomalyst/Imnovid, Abraxane and Otezla continue to perform well. Both Otezla and Pomalyst achieved blockbuster status in 2016, recording over $1 billion in sales.
Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. Securing reimbursement in additional countries, particularly in Japan, should boost the drug’s sales in international markets. Label expansion of these drugs will aid the top line.
Celgene is working on expanding Revlimid’s label further. Revlimid received FDA approval for use as a maintenance treatment in NDMM patients after they receive an autologous stem-cell transplant. The drug was also approved in the EU for the same.
Currently, a broad phase III program evaluating Revlimid in non-Hodgkin lymphoma (NHL) is underway.
Abraxane should maintain its position in the U.S. with stable market shares in breast, lung and pancreatic cancers. However, Abraxane sales are under pressure due to a highly competitive U.S. market for lung and breast cancer therapy.
The company did not provide any quarterly guidance but the annual guidance for 2017 was encouraging. For 2017, Celgene expects earnings around $7.10 to $7.25 per share. Net product sales are expected around $13.0–$13.4 billion. Revlimid sales are projected between $8 billion–$8.3 billion. Abraxane sales are still estimated to be around $1 billion.
On the first-quarter call, investors are expected to gain more visibility on the company’s performance and label expansion efforts, along with updates on the pipeline front.
Earnings Whispers
Our proven model does not conclusively show that Celgene is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately, that is not the case here, as elaborated below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is pegged at -0.68%. This is because the Most Accurate estimate is currently $1.46 while the Zacks Consensus Estimate is $1.47. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Celgene’s Zacks Rank #3 increases the predictive power of ESP, its negative ESP makes it highly unlikely for the stock to beat earnings this quarter.
As it is, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Amgen Inc. (AMGN - Free Report) has an Earnings ESP of +2.33% and a Zacks Rank #3. The company is scheduled to release results on Apr 26. You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences, Inc. GILD has an Earnings ESP of +2.77% and a Zacks Rank #3. The company is scheduled to release results on May 2.
Intercept Pharmaceuticals, Inc. has an Earnings ESP of +9.13% and a Zacks Rank #3. The company is expected to release results on May 4.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Celgene (CELG) to Post Q1 Earnings: What's in the Cards?
Celgene Corporation is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell. Last quarter, the company reported a negative earnings surprise of 1.40%.
Celgene outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past one year. The stock gained 10.5% during this period, compared with a decline of 14.4% for the industry.
Celgene’s track record has been pretty decent with the company beating earnings estimates thrice in the trailing four quarters. Overall, the company has delivered an average positive surprise of 5.08%.
Let's see how things are shaping up at the company ahead of this announcement.
Factors at Play
Celgene’s key product, Revlimid, should continue to act as the main growth driver in the first quarter, driven by share gains in important markets and longer treatment duration in newly diagnosed multiple myeloma (MM). Other key products – Pomalyst/Imnovid, Abraxane and Otezla continue to perform well. Both Otezla and Pomalyst achieved blockbuster status in 2016, recording over $1 billion in sales.
Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. Securing reimbursement in additional countries, particularly in Japan, should boost the drug’s sales in international markets. Label expansion of these drugs will aid the top line.
Celgene is working on expanding Revlimid’s label further. Revlimid received FDA approval for use as a maintenance treatment in NDMM patients after they receive an autologous stem-cell transplant. The drug was also approved in the EU for the same.
Currently, a broad phase III program evaluating Revlimid in non-Hodgkin lymphoma (NHL) is underway.
Abraxane should maintain its position in the U.S. with stable market shares in breast, lung and pancreatic cancers. However, Abraxane sales are under pressure due to a highly competitive U.S. market for lung and breast cancer therapy.
The company did not provide any quarterly guidance but the annual guidance for 2017 was encouraging. For 2017, Celgene expects earnings around $7.10 to $7.25 per share. Net product sales are expected around $13.0–$13.4 billion. Revlimid sales are projected between $8 billion–$8.3 billion. Abraxane sales are still estimated to be around $1 billion.
On the first-quarter call, investors are expected to gain more visibility on the company’s performance and label expansion efforts, along with updates on the pipeline front.
Earnings Whispers
Our proven model does not conclusively show that Celgene is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately, that is not the case here, as elaborated below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is pegged at -0.68%. This is because the Most Accurate estimate is currently $1.46 while the Zacks Consensus Estimate is $1.47. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Celgene’s Zacks Rank #3 increases the predictive power of ESP, its negative ESP makes it highly unlikely for the stock to beat earnings this quarter.
As it is, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Celgene Corporation Price and Consensus
Celgene Corporation Price and Consensus | Celgene Corporation Quote
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Amgen Inc. (AMGN - Free Report) has an Earnings ESP of +2.33% and a Zacks Rank #3. The company is scheduled to release results on Apr 26. You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences, Inc. GILD has an Earnings ESP of +2.77% and a Zacks Rank #3. The company is scheduled to release results on May 2.
Intercept Pharmaceuticals, Inc. has an Earnings ESP of +9.13% and a Zacks Rank #3. The company is expected to release results on May 4.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging
phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>